Moderna consistently appears in biotech industry news, notably for their
mRNA-based
vaccines. They continue to amass success stories in
birds flu and
RSV (Respiratory Syncytial Virus) vaccines, showing
promising early results and securing a $176 million investment from the US government for mRNA bird flu vaccine development. Contrarily, the market witnessed a slide in Moderna’s stock amidst industry competition and reports of disappointing earnings. A parallel narrative sees Moderna tackling other illnesses, advancing in
solid tumor vaccines and reportedly developing a drug offering hope against a devastating childhood disease. The company remains the subject of interest as it continues litigation over its mRNA patent alongside Pfizer and BioNTech. Albeit,
Jim Cramer’s disappointment in Moderna looms large as does the reported 20% stock fall due to dipping EU sales and a congested US vaccine market. Meteoric achievements like the FDA’s approval of Moderna’s mRNA RSV vaccine for older adults and
the positive Phase III data for their Covid-19/Influenza mRNA vaccine coexist with legal challenges from shareholders and halted plans for a Kenyan plant after the firm incurred a $1B loss.
Moderna MRNA News Analytics from Wed, 13 Dec 2023 08:00:00 GMT to Sun, 29 Sep 2024 16:00:45 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor 0
